Gynaecological endocrinology is concerned with the secretion of hormones by the ovary, the control of ovarian function by the pituitary and the manifestation of ovarian activity by the behaviour of the endometrium and the character and regularity of menstrual bleeding. It is necessary, therefore, to understand the physiology of ovarian hormone secretion, its control and manifestations, the nature of the disorders induced by abnormal ovarian function, the methods of investigating them, the preparations available for treating them and the principles and results of such treatment.
Physiology of the Ovary
The ovary contains a large number of primordial follicles distributed throughout the cortex. One of these, in turn, develops into the Graafian follicle that dominates each ovarian cycle. The Graafian follicle contains an ovum embedded in granulosa cells which secrete oestrogen into the follicular fluid. At ovulation the follicle ruptures and discharges the ovum which normally enters the Fallopian tube where it may become fertilized. The theca interna surrounding the follicle proliferates until its cells have infiltrated the follicular cavity converting it into a solid structure, the corpus luteum, which continues to secrete oestrogen but also characteristically produces progesterone. The corpus luteum has an inherent life span and in due course degenerates with diminishing secretion of its hormones, and thus abdicates in favour of the developing Graafian follicle of the next ovarian cycle.
The ovarian cycle is controlled by the pituitary gonadotrophic hormones. Evidence for the existence of three gonadotrophic hormones has been obtained in certain species, such as the rat. These are the follicle-stimulating hormone (F. Progestogens.-Progesterone has to be given by injection to be reasonably effective at an economic price. Ethisterone (07-ethinyl testosterone) is an orally effective progestogen in doses about ten times as great as parenteral progesterone. Recently a number of derivatives of i9-nortestosterone have been introduced which are as powerful as parenteral progesterone, or possibly even considerably more potent. The following have undergone fairly extensive clinical trials: ethinyl-nortestosterone, ethyl-nortestosterone, methyl-nortestosterone and ethinyl-oestraenolone. Progesterone is transient in its effect and should be administered daily or every other day. Esterification prolongs the effectiveness of steroids, but progesterone cannot be esterified because it contains no hydroxyl group. 17-hydroxyprogesterone caproate is said to be a potent progestogen which remains effective for about three weeks.
Androgens.---Testosterone is administered by injection in the form of its propionic ester, which remains effective for about three days. Testosterone phenylpropionate and testosterone oenanthate have a prolonged effect of up to three weeks. For oral or sublingual administration methyltestosterone is usually employed. It is claimed that other androgenic derivatives, such as methylandrostenediol and methylandrostanolone, both of which are given in the form of tablets for sublingual absorption, are primarily protein-anabolic and have comparatively little androgenic effect. They are therefore recommended as being less likely to induce undesirable side-effects such as acne and hirsutism. It is as yet not certain that these claims have been proved.
Gonadotrophins.-Two preparations are available: One is an extract of pregnant mare serum and is chiefly follicle-stimulating; the other is a preparation of chorionic gonadotrophin and is mainly luteinizing or luteotrophic. Both are effective only by intramuscular injection. The Endocrine Treatment of Menstrual Disorders
Oligomenorrhoea.-If it is established that ovulation is taking place endocrine therapy is unlikely to improve the patient's condition. If the problem is infertility the patient should be instructed to keep basal temperature records and aim to have intercourse when the temperature rises.
Menorrhagia.-As this is usually due to a relative lack of progesterone, it would seem logical to give progesterone in the second half of the cycle. In practice this has not been very successful, though it is possible that the new I9-nortestosterone compounds possessing potent progestational activity may prove to be more effective. There seems to be some doubt, however, as to whether they induce full secretory changes in the endometrium, and these are probably essential for the complete shedding of the endometrium that leads to normal menstrual bleeding. At intervals of 4 to Iz hours. To prevent this being followed in two or three days by an oestrogen withdrawal bleeding, the conjugated equine oestrogen is tapered off by giving conjugated equine oestrogen by mouth in daily doses of 7.5 mg. for a week, 5 mg. for a second week, and 2.5 mg. for a third week. If bleeding has not occurred during this time progesterone is injected in 25 mg. doses intramuscularly daily for four days and this should be followed in three or four days by a progesterone withdrawal bleeding which should resemble a normal period in amount and duration. Exactly a month after commencing the first course of progesterone injections another course is administered, or ethisterone 30 mg. daily by mouth for ten days is substituted for the injections. In this way a series of artificial progestogen withdrawal bleedings at monthly intervals prevents the endometrium building up into a condition of cystic glandular hyperplasia and breaking down to initiate another episode of metropathic bleeding. Limited experience of the recently introduced i9-nortestosterone compounds has led to claims that doses of about 20 mg. daily will induce haemostasis in three or four days and that subsequent courses of daily doses of io to 20 mg. for ten days or more will produce withdrawal bleeding from a true secretory endometrium; A few authors claim that chorionic gonadotrophin may in some cases induce ovulation and if repeated a number of times eventually give rise to spontaneous ovulatory cycles. In approximately half of a small series of women in which the metropathia was neither pubertal, puerperal nor premenopausal, ovulatory cycles continued for at least a year after cessation of the treatment, which consisted of giving 6oo I.U. of chorionic gonadotrophin daily for five injections, then a month later for four injections, then three injections and so on.
Amenorrhoea.-Experience of endocrine therapy in amenorrhoea has, in most clinics, been dis-appointing. It is nearly always possible to induce oestrogen withdrawal bleedings or, if the endometrium is sufficiently primed with endogenous oestrogen, progesterone withdrawal bleedings. In the majority of cases, however, such withdrawal bleedings do not lead subsequently to spontaneous ovulatory cycles. Most clinics have been equally disappointed with the results of gonadotrophin therapy. A few, however, claim spectacular success. In one clinic, for instance, administration of I,500 to 3,000 I.U. of serum gonadotrophin given daily for five injections, followed by I,5oo00 I.U. chorionic gonadotrophin on alternate days for three injections, has led, sometimes after repeated courses at monthly intervals, to spontaneous ovulatory cycles, and in some cases to pregnancy, in about 50 per cent. of women with low urinary gonadotrophin output and amenorrhoea of not more than two years' duration.
